var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)

RWE 101 – Challenges in RWE Generation (Regulatory Grade RWE?)

Real-world evidence (RWE) refers to data derived from real-world sources such as electronic health records, claims data, and patient-generated data, among others. The use of RWE has gained popularity in recent years as a means of providing insights into real-world patient experiences and improving healthcare decision-making. However, generating high-quality RWE presents several challenges, including:

[1] Data quality: The quality of RWE can vary significantly depending on the source of the data. For example, electronic health records may contain incomplete or inaccurate information, and claims data may not capture all relevant clinical information. Ensuring the accuracy and completeness of RWE requires careful validation and quality control measures.

[2] Data privacy and security: RWE often contains sensitive patient information, which raises concerns about data privacy and security. The use of RWE must comply with privacy regulations such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR) to protect patient confidentiality and prevent data breaches.

[3] Bias: RWE can be subject to bias due to differences in patient populations, data collection methods, and confounding factors. Addressing these sources of bias requires careful study design and statistical analysis to ensure that the results are accurate and unbiased.

[4] Data interoperability: RWE often comes from multiple sources, each with different data formats and structures. Ensuring interoperability between different data sources can be a significant challenge, requiring the use of standardized data formats and protocols.

[5] Ethics and consent: The use of RWE raises ethical concerns about patient consent and the potential for unintended consequences, such as stigmatization or discrimination. Ensuring that patients are informed and consent to the use of their data is critical to maintaining trust and ethical practice.

Overall, generating high-quality RWE requires careful attention to data quality, privacy and security, bias, data interoperability, and ethics and consent. Addressing these challenges can help to unlock the full potential of RWE in improving healthcare decision-making and patient outcomes.

Share this story...

Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)2023-08-07T11:29:05+00:00

Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations

RWE 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations

Real-world evidence (RWE) studies include observational studies that uses data collected in real-world settings to investigate the safety and effectiveness of drugs and medical devices. While RWE studies can provide valuable insights into the use of medications in real-world settings, pharmaceutical companies face several challenges when using these studies to support marketing authorizations:

1. Data quality and availability: The quality and availability of real-world data can be a significant challenge for pharmaceutical companies when running RWE studies. Data sources may be incomplete, inconsistent, or difficult to access, making it difficult to draw accurate conclusions from the data.

2. Data privacy and confidentiality: Data privacy and confidentiality regulations such as GDPR can make it difficult to obtain and use patient data for RWE studies. Companies may need to navigate complex legal frameworks to obtain the data they need while ensuring that patient privacy is protected.

3. Study design and bias: RWE studies are observational and not randomized controlled trials, which makes them more susceptible to bias. Companies need to carefully design and conduct RWE studies to minimize the risk of bias and ensure that the results are reliable and representative of real-world settings.

4. Data analysis and interpretation: Analyzing and interpreting RWE data can be challenging due to the complexity of the data and the potential for bias. Companies may need to employ advanced statistical techniques to ensure that the data is analyzed accurately and that the results are valid and reliable.

5. Regulatory acceptance: Regulatory authorities may be hesitant to accept RWE studies as evidence to support marketing authorizations. Companies need to work closely with regulatory authorities to ensure that their RWE studies meet the necessary standards for regulatory acceptance.

In conclusion, pharmaceutical companies face several challenges when running RWE studies to support marketing authorizations. To overcome these challenges, companies need to carefully design and conduct studies, ensure data quality and privacy, and work closely with regulatory authorities to demonstrate the validity and reliability of their results.

Share this story...

Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations2023-08-07T11:23:22+00:00
Go to Top